(EXEL) Exelixis - Ratings and Ratios
Cabozantinib, Cobimetinib, Minnebropan, Zanzalintinib, XL309
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 36.1% |
| Value at Risk 5%th | 47.6% |
| Relative Tail Risk | -19.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.83 |
| Alpha | 26.49 |
| CAGR/Max DD | 1.69 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.323 |
| Beta | 0.561 |
| Beta Downside | 0.230 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.34% |
| Mean DD | 6.40% |
| Median DD | 5.69% |
Description: EXEL Exelixis October 30, 2025
Exelixis, Inc. (NASDAQ:EXEL) is a U.S.-based oncology biotech that develops, markets, and sells targeted therapies for hard-to-treat cancers. Its flagship products are CABOMETYX (cabozantinib tablets) for advanced renal cell carcinoma post-anti-angiogenic therapy and COMETRIQ (cabozantinib capsules) for progressive metastatic medullary thyroid cancer; both inhibit multiple tyrosine kinases (MET, AXL, RET, VEGF). The company also commercializes COTELLIC (MEK inhibitor) in combination for advanced melanoma and MINNEBRO (mineralocorticoid-receptor antagonist) for hypertension in Japan.
Pipeline highlights include zanzalintinib (next-gen TKI targeting VEGF, MET, TAM kinases), XL309 (USP1 inhibitor for BRCA-mutated tumors), XB010 (5T4-directed ADC with MMAE payload), and XL495 (PKMYT1 inhibitor). Exelixis maintains a broad collaboration network with partners such as Ipsen, Takeda, Roche, Genentech, BMS, and Merck, leveraging co-development and licensing to diversify risk and accelerate access.
Recent performance metrics (FY 2023) show total revenue of roughly $1.2 billion, driven primarily by cabozantinib sales exceeding $1 billion, and a 12 % year-over-year increase in operating cash flow, reflecting strong market uptake in RCC and medullary thyroid cancer. The oncology biotech sector is benefitting from a projected 8 % CAGR through 2028, driven by aging populations, expanding indications for targeted agents, and sustained FDA approval pipelines.
For a deeper quantitative assessment of EXELs valuation, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (677.9m TTM) > 0 and > 6% of Revenue (6% = 137.3m TTM) |
| FCFTA 0.27 (>2.0%) and ΔFCFTA 12.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 44.95% (prev 55.50%; Δ -10.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.28 (>3.0%) and CFO 791.0m > Net Income 677.9m (YES >=105%, WARN >=100%) |
| Net Debt (-199.8m) to EBITDA (862.9m) ratio: -0.23 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (278.5m) change vs 12m ago -4.44% (target <= -2.0% for YES) |
| Gross Margin 96.63% (prev 96.25%; Δ 0.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.12% (prev 70.32%; Δ 8.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -20.75 (EBITDA TTM 862.9m / Interest Expense TTM -40.1m) >= 6 (WARN >= 3) |
Altman Z'' 4.04
| (A) 0.36 = (Total Current Assets 1.40b - Total Current Liabilities 373.8m) / Total Assets 2.82b |
| (B) -0.04 = Retained Earnings (Balance) -106.1m / Total Assets 2.82b |
| (C) 0.29 = EBIT TTM 833.1m / Avg Total Assets 2.89b |
| (D) -0.15 = Book Value of Equity -102.2m / Total Liabilities 662.8m |
| Total Rating: 4.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 92.75
| 1. Piotroski 7.0pt |
| 2. FCF Yield 6.48% |
| 3. FCF Margin 32.91% |
| 4. Debt/Equity 0.08 |
| 5. Debt/Ebitda -0.23 |
| 6. ROIC - WACC (= 21.70)% |
| 7. RoE 31.64% |
| 8. Rev. Trend 84.14% |
| 9. EPS Trend 74.07% |
What is the price of EXEL shares?
Over the past week, the price has changed by +0.11%, over one month by +4.69%, over three months by +13.98% and over the past year by +37.21%.
Is EXEL a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.3 | -2.1% |
| Analysts Target Price | 45.3 | -2.1% |
| ValueRay Target Price | 58.7 | 26.9% |
EXEL Fundamental Data Overview December 24, 2025
P/E Trailing = 18.625
P/E Forward = 15.3374
P/S = 5.4341
P/B = 5.4989
P/EG = 2.2685
Beta = 0.4
Revenue TTM = 2.29b USD
EBIT TTM = 833.1m USD
EBITDA TTM = 862.9m USD
Long Term Debt = 176.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last fiscal year)
Debt = 176.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -199.8m USD (from netDebt column, last quarter)
Enterprise Value = 11.62b USD (12.43b + Debt 176.5m - CCE 988.5m)
Interest Coverage Ratio = -20.75 (Ebit TTM 833.1m / Interest Expense TTM -40.1m)
FCF Yield = 6.48% (FCF TTM 753.1m / Enterprise Value 11.62b)
FCF Margin = 32.91% (FCF TTM 753.1m / Revenue TTM 2.29b)
Net Margin = 29.63% (Net Income TTM 677.9m / Revenue TTM 2.29b)
Gross Margin = 96.63% ((Revenue TTM 2.29b - Cost of Revenue TTM 77.2m) / Revenue TTM)
Gross Margin QoQ = 96.89% (prev 96.57%)
Tobins Q-Ratio = 4.12 (Enterprise Value 11.62b / Total Assets 2.82b)
Interest Expense / Debt = 14.91% (Interest Expense 26.3m / Debt 176.5m)
Taxrate = 23.31% (58.8m / 252.4m)
NOPAT = 638.9m (EBIT 833.1m * (1 - 23.31%))
Current Ratio = 3.75 (Total Current Assets 1.40b / Total Current Liabilities 373.8m)
Debt / Equity = 0.08 (Debt 176.5m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.23 (Net Debt -199.8m / EBITDA 862.9m)
Debt / FCF = -0.27 (Net Debt -199.8m / FCF TTM 753.1m)
Total Stockholder Equity = 2.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 24.01% (Net Income 677.9m / Total Assets 2.82b)
RoE = 31.64% (Net Income TTM 677.9m / Total Stockholder Equity 2.14b)
RoCE = 35.93% (EBIT 833.1m / Capital Employed (Equity 2.14b + L.T.Debt 176.5m))
RoIC = 29.82% (NOPAT 638.9m / Invested Capital 2.14b)
WACC = 8.13% (E(12.43b)/V(12.61b) * Re(8.08%) + D(176.5m)/V(12.61b) * Rd(14.91%) * (1-Tc(0.23)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.67%
[DCF Debug] Terminal Value 80.09% ; FCFE base≈613.8m ; Y1≈706.0m ; Y5≈990.6m
Fair Price DCF = 63.43 (DCF Value 17.01b / Shares Outstanding 268.1m; 5y FCF grow 17.57% → 3.0% )
EPS Correlation: 74.07 | EPS CAGR: 30.19% | SUE: 0.51 | # QB: 0
Revenue Correlation: 84.14 | Revenue CAGR: 7.79% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=+0.030 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=3.28 | Chg30d=-0.005 | Revisions Net=+0 | Growth EPS=+12.6% | Growth Revenue=+12.0%
Additional Sources for EXEL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle